Investment Rating - The report maintains a "Buy-A" rating for the company, indicating an expected price increase of over 15% compared to the benchmark index [7]. Core Views - The company is facing short-term performance pressure but is expected to benefit from its capabilities in independent research and acquisition strategies across the entire medical aesthetics industry chain [1][5]. - The company has recently reported a revenue of 2.453 billion yuan for 2025, a decrease of 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [1][4]. Financial Performance - For Q4 2025, the company achieved a revenue of 588 million yuan, representing a decline of 9.61%, and a net profit of 198 million yuan, down 46.85% [1]. - The company's gross margin for the period was 92.7%, a decrease of 1.94 percentage points, while the net profit margin was 53.07%, down 11.59 percentage points [4]. - The operating cash flow for the period was 1.324 billion yuan, a decline of 31.29% [4]. Revenue Breakdown - The company's revenue from solution and gel products was 1.265 billion yuan and 890 million yuan, respectively, reflecting year-on-year declines of 27.48% and 26.82% [3]. - The company reported revenue from new freeze-dried powder injection products of 208 million yuan [3]. - Revenue by region showed significant declines, with East China, North China, and South China experiencing decreases of 17.63%, 16.47%, and 23.3%, respectively [3]. Future Projections - The company is projected to achieve earnings per share (EPS) of 5.00, 5.41, and 6.06 yuan for the years 2026, 2027, and 2028, respectively [7]. - Corresponding price-to-earnings (P/E) ratios for these years are expected to be 23.7, 22.0, and 19.6 times [7]. Strategic Developments - The company is enhancing its product matrix with the upcoming launch of A-type botulinum toxin and minoxidil topical solution, which are currently in clinical trials [5]. - A significant acquisition was made by the company's subsidiary, acquiring 85% of South Korean REGEN for 190 million USD, which is expected to strengthen its position in the global medical aesthetics market [5].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the innovative drug sector is currently the core focus, supported by favorable domestic policies such as the NMPA's "Spring Rain Action" to promote clinical innovation in medical devices [4][5]. - The total amount of innovative drug licensing transactions in China exceeded $60 billion in the first three months of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. - The report suggests focusing on companies with core technology platforms and differentiated pipeline layouts, particularly those expected to achieve positive catalysts at major academic conferences like AACR [5]. Important Industry News - The NMPA has initiated a three-year "Spring Rain Action" to support the transformation of clinical innovation in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has been approved by the FDA, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has received FDA approval, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, making it the first of its kind domestically [46]. Company Dynamics - Novartis plans to invest over 3.3 billion RMB in China to enhance its R&D, production, and operational capabilities [48].

Investment Rating - The report maintains a "Buy-A" rating for the company, indicating a positive outlook for its stock performance in the next 6-12 months [1][7]. Core Insights - The company is facing short-term performance pressure but is expected to benefit from its capabilities in independent research and acquisitions across the entire medical beauty industry chain [1][3]. - The company reported a revenue of 2.453 billion yuan for 2025, a decrease of 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [3][9]. - The company is expanding its product matrix with new products in clinical trials and has made strategic acquisitions to enhance its global presence in the medical beauty market [5][9]. Financial Performance - The company’s revenue for Q4 2025 was 588 million yuan, reflecting a decline of 9.61% year-on-year, while the net profit for the same period was 198 million yuan, down 46.85% [3][4]. - The gross margin for the period was 92.7%, a decrease of 1.94 percentage points, and the net profit margin was 53.07%, down 11.59 percentage points [4][9]. - The company plans to distribute a cash dividend of 8 yuan per 10 shares to all shareholders [3]. Future Projections - The expected earnings per share (EPS) for 2026, 2027, and 2028 are projected to be 5.00 yuan, 5.41 yuan, and 6.06 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 23.7, 22.0, and 19.6 [7][9]. - Revenue is projected to recover to 2.702 billion yuan in 2026, with a year-on-year growth of 10.2% [9][11].

Financial Performance - In 2025, the company achieved a revenue of CNY 33.282 billion, a year-on-year decline of 9.38% [2] - Net profit for 2025 was CNY 8.451 billion, down 28.01% year-on-year, with a non-recurring net profit of CNY 8.362 billion, a decrease of 27.28% [2] - Operating cash flow net amount was CNY 10.145 billion, down 18.40% year-on-year [2] - In Q4 2025, revenue was CNY 7.448 billion, a 2.86% increase year-on-year, while net profit decreased by 38.54% to CNY 0.638 billion [2] Shareholder Returns - The company has maintained a consistent dividend policy since its A-share listing in 2018, with total dividends amounting to approximately CNY 37.336 billion by the end of last year [3] - For 2025, the proposed cash dividend distribution is CNY 3.76 billion, with total cash dividends for the year expected to reach CNY 5.310 billion, accounting for 65.27% of the annual net profit [3] International Business Performance - International revenue reached CNY 17.650 billion, a year-on-year increase of 7.40%, accounting for 53% of total revenue [4] - The European market saw a 17% growth in 2025, building on a high growth base from 2024 [4] - Emerging international business segments grew nearly 30% year-on-year [4] Domestic Business Performance - Domestic revenue was CNY 15.632 billion, a decline of 22.97% year-on-year [6] - The domestic medical device industry has faced significant adjustments, with procurement budgets under pressure, leading to a weak recovery phase [7] - The in vitro diagnostics (IVD) sector has entered a contraction phase, with reagent usage and prices declining [7] Product Line Performance - The in vitro diagnostics segment generated CNY 12.241 billion, a decrease of 9.41%, making it the largest revenue contributor at approximately 37% of total revenue [8] - The life information and support segment reported CNY 9.837 billion, down 19.80%, with international revenue accounting for 74% [9] - The medical imaging segment achieved CNY 5.717 billion, a decline of 18.02%, with international revenue at 65% [11] - Emerging business segments generated CNY 5.378 billion, a year-on-year increase of 38.85%, accounting for about 16% of total revenue [12] R&D Investment and New Products - R&D investment for 2025 was CNY 3.929 billion, representing 11.80% of revenue [14] - New product launches included various diagnostic kits and automated systems aimed at enhancing market competitiveness [14][15] Future Outlook - The company aims to deepen its overseas localization and high-end strategic customer penetration, particularly in the European and emerging markets [5] - The domestic business is expected to achieve positive growth in 2026, with a stable growth phase anticipated from 2027 onwards [36] - The IVD business is projected to be a key growth driver, with plans to double market share in the next three years [30] Market Challenges and Strategies - The company faces challenges from high inflation and procurement budget cuts in the domestic market, impacting profitability [40] - Strategies include enhancing product competitiveness and expanding into new markets, particularly in IVD and emerging business segments [31][37]

Investment Rating - The report upgrades the investment rating to "Buy" for the company, indicating an expected relative performance increase of over 15% against the benchmark index in the next 6 to 12 months [17]. Core Insights - The company achieved a significant revenue increase of 22.90% year-on-year in 2025, reaching 2.251 billion yuan, and a net profit increase of 39.73%, amounting to 650 million yuan, exceeding market expectations [4][5]. - The fourth quarter of 2025 saw a remarkable revenue growth of 47.66% year-on-year, with net profit soaring by 139.17% [4][5]. - The company is positioned as a leader in the detector industry, with a focus on expanding its product and technology offerings, particularly in the context of the AI application wave and the growth of silicon-based OLED backplanes [12][13]. Financial Performance Summary - Revenue projections for the company are as follows: 1.831 billion yuan in 2024, 2.251 billion yuan in 2025, 3.512 billion yuan in 2026, 4.693 billion yuan in 2027, and 5.736 billion yuan in 2028, with growth rates of -2%, 23%, 56%, 34%, and 22% respectively [3]. - The net profit forecast shows a trajectory from 465 million yuan in 2024 to 1.238 billion yuan in 2028, with growth rates of -23%, 40%, 27%, 25%, and 20% respectively [3]. - The company maintains a stable gross margin of 51.36% in 2025, reflecting a year-on-year increase of 1.25 percentage points, and a net profit margin of 28.09%, up by 3.50 percentage points [7]. Operational and Cash Flow Analysis - The company improved its inventory turnover days to 266.43 days, a decrease of 44.85 days year-on-year, indicating enhanced inventory management [8]. - The net cash flow from operating activities reached 1.302 billion yuan in 2025, representing a year-on-year increase of 261.19% [8]. - R&D expenses for 2025 were 340 million yuan, accounting for 15.09% of revenue, with a year-on-year growth of 9.52% [8]. Market Position and Growth Potential - The global market for digital X-ray imaging equipment is projected to grow significantly, with a compound annual growth rate (CAGR) of 4.79% from 2021 to 2030, reaching 47.61 billion USD by 2030 [9]. - The company holds a 19.83% market share in the global digital X-ray detector market as of 2024, positioning it as a leading player [10]. - The silicon-based OLED microdisplay market is expected to grow at a CAGR of 34.3%, with the company aiming to become a core supplier in this segment [12][13].

Investment Rating - The report upgrades the investment rating to "Buy" [3][13]. Core Insights - The company achieved a significant revenue increase of 22.90% year-on-year in 2025, reaching 2.251 billion yuan, with a net profit growth of 39.73% to 650 million yuan [4][6]. - The fourth quarter of 2025 saw a remarkable revenue growth of 47.66% year-on-year, with net profit soaring by 139.17% [4][5]. - The company is positioned as a leader in the detector industry, with expectations for continued growth driven by advancements in AI applications and the expansion of silicon-based OLED backplane production [13]. Financial Performance Summary - Revenue and Profit Forecasts: - 2024A: Revenue of 1.831 billion yuan, net profit of 465 million yuan - 2025A: Revenue of 2.251 billion yuan, net profit of 650 million yuan - 2026E: Revenue of 3.512 billion yuan, net profit of 826 million yuan - 2027E: Revenue of 4.693 billion yuan, net profit of 1.035 billion yuan - 2028E: Revenue of 5.736 billion yuan, net profit of 1.238 billion yuan [3][14]. - Profitability Metrics: - Gross margin for 2025 was 51.36%, an increase of 1.25 percentage points year-on-year - Net profit margin for 2025 was 28.09%, up by 3.50 percentage points year-on-year [7][8]. - Cash Flow and Operational Efficiency: - Operating cash flow for 2025 was 1.302 billion yuan, reflecting a 261.19% increase year-on-year - Inventory turnover days decreased by 44.85 days to 266.43 days, indicating improved inventory management [8][9]. Market Position and Growth Potential - The global X-ray imaging equipment market is projected to grow from $21.76 billion in 2015 to $47.61 billion by 2030, with a compound annual growth rate (CAGR) of 4.79% from 2021 to 2030 [9][10]. - The company holds a 19.83% market share in the global digital X-ray detector market as of 2024, indicating a strong competitive position [10][12]. - The silicon-based OLED microdisplay market is expected to grow at a CAGR of 34.3%, reaching 67.93 billion yuan by 2030, presenting significant growth opportunities for the company [12][13].

Investment Rating - The report maintains a "Buy" rating for Angelalign, with an expected target price of HKD 91.89, reflecting a potential upside of 22.8% from the current price of HKD 72.85 [4][6]. Core Insights - Angelalign reported strong fiscal year 2025 results, with revenue increasing by 37.8% year-on-year to USD 370 million and net profit rising by 134.7% to USD 28 million, exceeding estimates by 9% and 140% respectively [1][4]. - The company's total shipment volume grew by 48.1% to 532,400 units, driven by rapid overseas expansion and continued market share growth in the domestic market [1]. - The overseas business remains a key growth driver, with overseas revenue up 102.5% to USD 163 million, and case volume increasing by 82.1% to approximately 256,200 units [2]. - Domestic performance showed resilience, with revenue growing by 10.1% to USD 207 million and case shipment volume increasing by 26.3% to approximately 276,200 units, indicating a more rational competitive landscape [3]. Summary by Sections Financial Performance - For fiscal year 2025, Angelalign's revenue reached USD 370 million, with a year-on-year growth rate of 37.8%. The adjusted net profit was USD 44 million, reflecting a 63.0% increase [5]. - The forecast for fiscal year 2026 anticipates revenue of USD 450 million, representing a 21.4% growth, while adjusted net profit is expected to be USD 56 million, a 28.9% increase [5][11]. Profitability and Margins - The report notes a significant improvement in profitability, with the gross profit margin in the domestic market increasing by 2 percentage points to 65%, offsetting average selling price pressures [3]. - Despite anticipated challenges from global capacity expansion and rising intellectual property litigation costs, the overall profitability is expected to remain strong [1][4]. Valuation Metrics - The report applies a price-to-earnings (P/E) ratio of 18x for the domestic business and a price-to-sales (P/S) ratio of 5x for the faster-growing overseas business, aligning with industry peers [4]. - The target price of HKD 91.89 is derived from a sum-of-the-parts (SOTP) valuation, indicating a robust outlook for both domestic and international operations [10].

Investment Rating - The investment rating for Haier Biomedical is maintained at "Buy" [1][5][13] Core Views - The company achieved a revenue of 2.329 billion yuan in 2025, reflecting a year-on-year growth of 1.96%, while the net profit attributable to the parent company was 251 million yuan, down 31.61% due to trade frictions, industry demand recovery, and long-term strategic investments [5][6] - The company is experiencing a steady recovery in the domestic market and is expanding its overseas presence, with overseas revenue reaching 840 million yuan in 2025, a growth of 17.9%, accounting for 36% of total revenue [6][7] - The company has a strong focus on research and development, with R&D investment of 320 million yuan and a significant increase in the number of patents, leading to a 48.5% contribution from new industries to total revenue [7][8] Financial Summary - In 2025, the gross margin was 46.79%, a decrease of 1.20 percentage points, while the net margin was 10.96%, down 5.73 percentage points [5][11] - The company forecasts net profits for 2026, 2027, and 2028 to be 278 million yuan, 322 million yuan, and 379 million yuan respectively, with corresponding EPS of 0.88 yuan, 1.02 yuan, and 1.20 yuan [5][8] - The P/E ratios for 2026, 2027, and 2028 are projected to be 35.9, 30.9, and 26.3 respectively, indicating a favorable valuation trend [5][8]

Investment Rating - The investment rating for Haier Biomedical is maintained as "Buy" [1][5][13] Core Views - The company achieved a revenue of 2.329 billion yuan in 2025, reflecting a year-on-year growth of 1.96%, while the net profit attributable to the parent company was 251 million yuan, down 31.61% due to trade frictions and strategic investments [5][6] - The company is experiencing a steady recovery in the domestic market and is expanding its overseas presence, with overseas revenue reaching 840 million yuan in 2025, a growth of 17.9%, accounting for 36% of total revenue [6][7] - The company has a strong focus on research and development, with R&D expenses amounting to 320 million yuan, and a significant increase in the number of patents and new product launches [7] Financial Summary - Revenue projections for 2026-2028 are estimated at 2.561 billion yuan, 2.819 billion yuan, and 3.144 billion yuan respectively, with expected growth rates of 10.0%, 10.1%, and 11.5% [8][10] - The net profit attributable to the parent company is projected to be 278 million yuan in 2026, 322 million yuan in 2027, and 379 million yuan in 2028, with corresponding EPS of 0.88 yuan, 1.02 yuan, and 1.20 yuan [8][10] - The company's gross margin is expected to stabilize around 46.8% for 2026, with a net margin of 10.9% [11]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立正 達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《審計報告》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2026年3月31日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；本公 司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供識別 北京市春立正达医疗器械股 份有限公司 审 计 报 告 ...